Completed PHASE2 INTERVENTIONAL 3-arm NCT00117208

Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis

A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis

Sponsor: Syntara

Conditions Cystic Fibrosis

Interventions Dornase alpha mannitol mannitol + pulmozyme

Updated 6 times since 2017 Last updated: Jan 31, 2010 Started: Nov 30, 2005 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cystic Fibrosis, this trial is completed. The trial is conducted by Syntara and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2024 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Syntara

Data source: Syntara

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom